MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

Search

Twist Bioscience Corp

Закрыт

СекторЗдравоохранение

42.3 -1.54

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

41.64

Макс.

43.23

Ключевые показатели

By Trading Economics

Доход

-48M

-27M

Продажи

3M

99M

Рентабельность продаж

-27.41

Сотрудники

979

EBITDA

3.2M

-21M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+0.14% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

2 февр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

669M

2.5B

Предыдущая цена открытия

43.84

Предыдущая цена закрытия

42.3

Новостные настроения

By Acuity

50%

50%

141 / 352 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

26 янв. 2026 г., 23:49 UTC

Популярные акции

Stocks to Watch: Agilysys, Nucor, Humana, UnitedHealth

26 янв. 2026 г., 23:09 UTC

Главные движущие силы рынка

Health Insurers' Shares Fall After Government Proposes Flat Medicare Advantage Rate

26 янв. 2026 г., 23:52 UTC

Обсуждения рынка

Gold's Path of Least Resistance Still Looks Higher, Technical Analysis Shows -- Market Talk

26 янв. 2026 г., 23:46 UTC

Обсуждения рынка

Nikkei May Decline as Yen's Rebound Raises Caution Over Earnings -- Market Talk

26 янв. 2026 г., 23:37 UTC

Обсуждения рынка

Gold Rises Amid Concerns Over Tariffs -- Market Talk

26 янв. 2026 г., 22:41 UTC

Обсуждения рынка

Australian 4Q CPI To Provide Smoking Gun For Hike -- Market Talk

26 янв. 2026 г., 22:26 UTC

Отчет

Karoon Expects Capex of US$110 Million-US$135 Million in 2026

26 янв. 2026 г., 22:26 UTC

Отчет

Karoon Expects Operating Costs to Fall Once Transition of Bauna FPSO Operatorship Completes

26 янв. 2026 г., 22:25 UTC

Отчет

Karoon Energy Expects Unit Production Cost of US$12-US$15/BOE in 2026

26 янв. 2026 г., 22:25 UTC

Отчет

Karoon Energy Expects Output to Rise in 2H Following Bauna Investment Program

26 янв. 2026 г., 22:25 UTC

Отчет

Karoon Energy Expects Output of 8.1 Million-9.2 Million BOE in 2026

26 янв. 2026 г., 22:24 UTC

Отчет

Karoon Energy 4Q Sales Revenue US$156.1 Million

26 янв. 2026 г., 22:23 UTC

Отчет

Karoon Energy 4Q Sales Volumes 2.65 Million BOE, Up 5% on Quarter

26 янв. 2026 г., 22:23 UTC

Отчет

Karoon Energy: Bauna FPSO Efficiency Increased to 98.8%

26 янв. 2026 г., 22:23 UTC

Отчет

Karoon Energy FY Oil, Natural Gas Production 10.3 Million BOE

26 янв. 2026 г., 22:22 UTC

Отчет

Karoon Energy 4Q Oil, Natural Gas Production 2.37 Million BOE

26 янв. 2026 г., 22:05 UTC

Приобретения, слияния, поглощения

Fortescue: Alta Copper Shareholders Approve Takeover

26 янв. 2026 г., 22:02 UTC

Приобретения, слияния, поглощения

Senate Antitrust Panel Chair Raises Concerns Over Netflix-Warner Deal -- WSJ

26 янв. 2026 г., 21:50 UTC

Обсуждения рынка
Отчет

Financial Services Roundup: Market Talk

26 янв. 2026 г., 21:50 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

26 янв. 2026 г., 21:34 UTC

Отчет

Nucor: Steel Products Segment Expected Improved Earnings in 1Q Due to Increased Volumes on Stable Pricing >NUE

26 янв. 2026 г., 21:34 UTC

Отчет

Nucor: Steel Mills Segment Expected Increase Is Due to Higher Volumes and Higher Realized Prices Across All Major Pdt Categories >NUE

26 янв. 2026 г., 21:34 UTC

Отчет

Nucor: Raw Materials Segment Is Expected to Have Increased Earnings in 1Q >NUE

26 янв. 2026 г., 21:34 UTC

Отчет

Nucor: 1Q Earnings Expected to Increase Across All Three Operating Segments, With the Largest Increase in Steel Mills Segment >NUE

26 янв. 2026 г., 21:30 UTC

Приобретения, слияния, поглощения

Eaton Stock Rises on Spin-Off Plan. Why It's Going All-In on Planes and AI Data Centers. -- Barrons.com

26 янв. 2026 г., 21:30 UTC

Отчет

Nucor 4Q Sales $7.69B >NUE

26 янв. 2026 г., 21:30 UTC

Отчет

Nucor 4Q Net $378M >NUE

26 янв. 2026 г., 21:30 UTC

Отчет

Nucor 4Q Steel Mills Total Shipments 5.91M Tons >NUE

26 янв. 2026 г., 21:30 UTC

Отчет

Nucor 4Q Total Tons Shipped to Outside Customers Down 9% >NUE

26 янв. 2026 г., 21:30 UTC

Отчет

Nucor 4Q EPS $1.64 >NUE

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

0.14% рост

Прогноз на 12 месяцев

Средняя 43 USD  0.14%

Максимум 50 USD

Минимум 39 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

6

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

141 / 352Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat